BennettJE. Antifungal agents. In: MandellGL, DouglasRG, BennettJE, eds. Principles and practices of infectious diseases.2nd ed.New York: John Wiley & Sons, 1985: 266–7.
3.
SchonebeckJ, PolakA, FernexM, ScholerHJ. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function.Chemotherapy1973; 18: 321–36.
4.
KucersH, BennettN. The use of antibiotics.London: William Heinemann Medical Books, 1979: 885–97.
5.
DiasioRB, LakingsDE, BennettJE. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.Antimicrob Agents Chemother1978; 14: 903–8.
6.
FinnC, SadeeW. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution mass fragmentography.Cancer Chemother Rep1975; 59: 279–86.
7.
KoefflerHP, GoldeDW. 5-fluorocytosine: inhibition of hematopoiesis in vitro and reversal of inhibition by uracil.J Infect Dis1979; 139: 438–43.
8.
WadeDN, SudlowG. The kinetics of 5-fluorocytosine elimination in man.Aust NZ J Med1972; 2: 153–8.
9.
KauffmanCA, FramePT. Bone marrow toxicity associated with 5-flucytosine therapy.Antimicrob Agents Chemother1977; 11: 244–7.
10.
UtzJP, GarriguesIL, SandeMA. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.Br J Infect Dis1975; 132: 368–73.
11.
Tester-DalderupCBM. Antifungal drugs. In: DukesMNG, ed. Meyler's side effects of drugs.10th ed.New York: Elsevier, 1984: 517–9.
